Pharus Sicav Biotech changes its name to Pharus Sicav Medical Innovation

Pharus Sicav Biotech changes its name to Pharus Sicav Medical Innovation

The fund, focused on companies operating in the biotechnology sector and at the forefront in the field of medical innovation, changed its name from December 1, 2020, in order to better distinguish its strategy from that of traditional Biotech sub-funds.


The fund's strategy is to select companies active both in the research of innovative drugs based on the most advanced biotechnologies and in possession of interesting technologies that could be used for the development of innovative therapies, applicable to various areas including the health care industry. The fund also focuses on small and medium-sized companies, which invest more in research and development, and which are meant  to be the protagonists of medical innovation.


Hence the name Pharus Sicav Medical Innovation: Pharus focuses on those highly innovative companies in the biotechnology field that carry out pharmaceutical research and which  will potentially become the leaders of tomorrow.

Information message - The information in this message is produced for information purposes only and therefore does not qualify as offer or recommendation or solicitation to buy or sell securities or financial instruments in general, financial products or services or investment, nor an exhortation to carry out transactions related to a specific financial instrument.
The contents of this informative message are the result of the free interpretation, evaluation and appreciation of Pharus Asset Management SA and constitute simple food for thought.
Any information and data indicated have a purely informative purpose and do not in any way represent an investment advisory service: the resulting operational decisions are to be considered taken by the user in full autonomy and at his own exclusive risk.
Pharus Asset Management SA dedicates the utmost attention and precision to the information contained in this message; nevertheless, no liability shall be accepted for errors, omissions, inaccuracies or manipulations by third parties on what is materially processed capable of affecting the correctness of the information provided and the reliability of the same, as well as for any result obtained using the said information.
It is not permitted to copy, alter, distribute, publish or use these contents on other sites for commercial use without the specific authorization of Pharus Asset Management SA.
Back to all news

Related News


Pharus Sicav Best Regulated Companies distributes the fourth dividend


Biotech: a stop that will not last


What impact will inflation have on corporate earnings?


China: opportunities within the revolution


The BoLe Chronicle | August 2021


Post-COVID, new opportunities for Biotech


Pharus Sicav Best Regulated Companies distributes the third dividend


The BoLe Chronicle | May 2021


Inflation: temporary or not?